RT Journal Article
SR Electronic
T1 Racial Inequalities in Alcohol Use Disorder Diagnosis in a Sample of 700,000 Veterans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.14.21256113
DO 10.1101/2021.07.14.21256113
A1 Rachel Vickers-Smith
A1 Amy C. Justice
A1 William C. Becker
A1 Christopher T. Rentsch
A1 Brenda Curtis
A1 Anita Fernander
A1 Emily E. Hartwell
A1 Eseosa T. Ighodaro
A1 Rachel L. Kember
A1 Janet Tate
A1 Henry R. Kranzler
YR 2021
UL http://medrxiv.org/content/early/2021/07/18/2021.07.14.21256113.abstract
AB Background Studies show that Black and Hispanic Veterans have a higher prevalence of alcohol use disorder (AUD) than White Veterans. We examined whether the relationship between self-reported race/ethnicity and AUD diagnosis varies by self-reported alcohol consumption.Methods The sample included 700,013 Black, Hispanic, and White Veterans enrolled in the Million Veteran Program cohort. Alcohol consumption was defined as an individual’s maximum score on the Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) questionnaire, a screen for hazardous or harmful drinking. The primary outcome, AUD, was defined by the presence of ICD-9/10 codes in the electronic health record. We used logistic regression with interactions to assess the association between race/ethnicity and AUD by maximum AUDIT-C score.Results Black and Hispanic Veterans were more likely to have an AUD diagnosis than White Veterans despite similar levels of alcohol consumption. The difference was greatest between Black and White men. At all but the lowest and highest levels of alcohol consumption, Black men had 24%-111% greater odds of an AUD diagnosis. The association between race/ethnicity and AUD diagnosis remained after adjustment for alcohol consumption, alcohol-related disorders, and other potential confounders.Conclusions The large discrepancy in AUD diagnosis across groups despite a similar distribution of alcohol consumption measures suggests that Veterans are differentially assigned an AUD diagnosis by race/ethnicity. Efforts are needed to examine the causes of the observed differences and to implement changes, such as structured diagnostic methods, to address a likely contributor to racial differences (i.e., bias) in AUD diagnosis.Competing Interest StatementDr. Kranzler is a member of an advisory board for Dicerna Pharmaceuticals, a consultant to Sophrosyne Pharmaceuticals, and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Dicerna, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. Dr. Kranzler is named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018. The other authors have no disclosures to make.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #I01 BX003341 and the Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. This research was supported in part by the Intramural Research Program of the NIH, NIDA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MVP received approval from the Central Veterans Affairs Institutional Review Board (IRB) and site-specific IRBs. All relevant ethical regulations for work with human subjects were followed in the conduct of the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData described in the manuscript will not be made available to other researchers for purposes of reproducing the results or replicating the procedure, in order to comply with current VA privacy regulations pursuant to the US Department of Veterans Administration policies on compliance with the confidentiality of US Veterans' data.